Revance Therapeutics (NASDAQ:RVNC) Price Target Raised to $29.00

Revance Therapeutics (NASDAQ:RVNCGet Rating) had its price objective hoisted by stock analysts at HC Wainwright from $25.00 to $29.00 in a report released on Friday, The Fly reports. HC Wainwright’s price objective points to a potential upside of 14.62% from the company’s previous close.

A number of other equities analysts have also weighed in on RVNC. Cowen increased their target price on Revance Therapeutics from $55.00 to $65.00 in a research note on Thursday. Wells Fargo & Company increased their price target on Revance Therapeutics from $17.00 to $24.00 and gave the company an “equal weight” rating in a research note on Thursday, August 25th. Cowen raised their target price on Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday. Needham & Company LLC raised their target price on Revance Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Guggenheim raised their target price on Revance Therapeutics to $35.00 in a research report on Monday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Revance Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $39.75.

Revance Therapeutics Stock Up 21.6 %

RVNC stock opened at $25.30 on Friday. The company has a debt-to-equity ratio of 14.80, a current ratio of 3.38 and a quick ratio of 3.20. The stock has a market capitalization of $1.85 billion, a P/E ratio of -6.57 and a beta of 0.92. The business has a 50-day moving average of $18.31 and a 200-day moving average of $16.63. Revance Therapeutics has a fifty-two week low of $11.27 and a fifty-two week high of $30.00.

Revance Therapeutics (NASDAQ:RVNCGet Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.03. Revance Therapeutics had a negative return on equity of 497.77% and a negative net margin of 265.04%. The company had revenue of $28.37 million during the quarter, compared to analysts’ expectations of $27.64 million. On average, sell-side analysts anticipate that Revance Therapeutics will post -3.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revance Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Advisor Group Holdings Inc. grew its position in shares of Revance Therapeutics by 60.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,071 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Revance Therapeutics during the 2nd quarter valued at $92,000. Prospera Financial Services Inc purchased a new position in shares of Revance Therapeutics during the 1st quarter valued at $122,000. Corton Capital Inc. purchased a new position in shares of Revance Therapeutics during the 2nd quarter valued at $162,000. Finally, Sciencast Management LP purchased a new position in shares of Revance Therapeutics during the 2nd quarter valued at $165,000. Institutional investors own 77.08% of the company’s stock.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Further Reading

The Fly logo

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.